Related references
Note: Only part of the references are listed.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Association between response to triptans and response to erenumab: real-life data
Ilaria Frattale et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials
Zeya Yan et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system
Alejandro Labastida-Ramirez et al.
PAIN (2020)
Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
Bixi Gao et al.
FRONTIERS IN NEUROLOGY (2020)
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
Jill C. Rau et al.
CEPHALALGIA (2020)
Medication overuse headache: Divergent effects of new acute antimigraine drugs
Philip R. Holland et al.
CEPHALALGIA (2020)
Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women
Tobias Kurth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Differential medication overuse risk of novel anti-migraine therapeutics
Chonlawan Saengjaroentham et al.
BRAIN (2020)
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans
Tessa de Vries et al.
PHARMACOLOGY & THERAPEUTICS (2020)
CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera-Mancilla et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
Danuta Szkutnik-Fiedler
PHARMACEUTICS (2020)
Neurovascular mechanisms of migraine and cluster headache
Jan Hoffmann et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2019)
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
Jan de Hoon et al.
CEPHALALGIA (2019)
Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials
Da Xu et al.
CEPHALALGIA (2019)
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
Simona Lattanzi et al.
DRUGS (2019)
Pharmacokinetics and pharmacodynamics of new acute treatments for migraine
Chiara Lupi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Valentina Favoni et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Erenumab: from scientific evidence to clinical practicethe first Italian real-life data
Piero Barbanti et al.
NEUROLOGICAL SCIENCES (2019)
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
Damiana Scuteri et al.
FRONTIERS IN PHARMACOLOGY (2019)
Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report
Stephen Aradi et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2019)
Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan
Eloisa Rubio-Beltran et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
CGRP-targeted antibodies in difficult-to-treat migraine
Tessa de Vries et al.
NATURE REVIEWS NEUROLOGY (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Erenumab safety and efficacy in migraine A systematic review and meta-analysis of randomized clinical trials
Changyu Zhu et al.
MEDICINE (2019)
Side effects associated with current and prospective antimigraine pharmacotherapies
Abimael Gonzalez-Hernandez et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Migraine is first cause of disability in under 50s: will health politicians now take notice?
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
Katrine Falkenberg et al.
JOURNAL OF HEADACHE AND PAIN (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
Eloisa Rubio-Beltran et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects
Ahmed N. Mahmoud et al.
BMJ OPEN (2018)
Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential
Andrea Negro et al.
JOURNAL OF PAIN RESEARCH (2018)
The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects
Zizheng Kee et al.
FRONTIERS IN PHYSIOLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Debbie L. Hay et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan
K. Ibrahimi et al.
CEPHALALGIA (2017)
The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Carlos M. Villalon et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2017)
Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
Messoud Ashina et al.
NEUROLOGY (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
OCT1 Mediates Hepatic Uptake of Sumatriptan and Loss-of-Function OCT1 Polymorphisms Affect Sumatriptan Pharmacokinetics
J. Matthaei et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Theo Vos et al.
LANCET (2016)
Recent advances in migraine therapy
Fabio Antonaci et al.
SPRINGERPLUS (2016)
CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
Lars Edvinsson
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY
F. A. Russell et al.
PHYSIOLOGICAL REVIEWS (2014)
Understanding and preventing drug-drug and drug-gene interactions
Cara Tannenbaum et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
Medication-overuse headache: epidemiology, diagnosis and treatment
Espen Saxhaug Kristoffersen et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine
Simon Akerman et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Taking the Negative View of Current Migraine Treatments The Unmet Needs
Peer Tfelt-Hansen et al.
CNS DRUGS (2012)
Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system
Malgorzata Filip et al.
PHARMACOLOGICAL REPORTS (2009)
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs
Carlos M. Villalon et al.
PHARMACOLOGY & THERAPEUTICS (2009)
The discovery of a new drug class for the acute treatment of migraine
Patrick P. A. Humphrey
HEADACHE (2007)
Calcitonin gene-related peptide (CGRP) and migraine
PL Durham
HEADACHE (2006)
Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries:: relationship to clinical effect
L Edvinsson et al.
CLINICAL SCIENCE (2005)
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack
G Juhasz et al.
CEPHALALGIA (2005)
Triptan nonresponder studies: Implications for clinical practice
DW Dodick
HEADACHE (2005)
Correlation between lipophilicity and triptan outcomes
J Pascual et al.
HEADACHE (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Triptans in migraine - The risks of stroke, cardiovascular disease, and death in practice
GC Hall et al.
NEUROLOGY (2004)
The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation
A Haimeur et al.
CURRENT DRUG METABOLISM (2004)
5-HT1 Receptors
Laurence Lanfumey et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2004)
Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and in situ hybridization
RWM van den Broek et al.
CEPHALALGIA (2002)
Advances in pharmacological treatment of migraine
HC Diener et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents - A comparative review
SS Jhee et al.
CLINICAL PHARMACOKINETICS (2001)
Triptans in migraine - A comparative review of pharmacology, pharmacokinetics and efficacy
P Tfelt-Hansen et al.
DRUGS (2000)
Current and emerging second-generation triptans in acute migraine therapy: A comparative review
D Deleu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
